The most commonly used receptor-targeting agent in the treatment of patients diagnosed with HER2+ (overexpressed in approximately 25–30% of breast tumors) breast cancer is trastuzumab (Tmab). This evidence concerns the gene ERBB2 and breast carcinoma.